Abstract
Three rabbit vessels, the carotid and pulmonary arteries and the jugular vein were investigated to identify vascular monoreceptor systems (either ETA or ETB) to be used in structure-activity studies on endothelins and their antagonists. The RbCA has been found to behave as a monoreceptor ETA preparation, since it shows much greater sensitivity to ET-1 than to ET-3 and is insensitive to IRL 1620. The contractile response of the RbCA to ET-1 is reduced in the presence of BQ-123 but is not influenced by BQ-788. The RbPA behaves as a pure ETB system when stimulated with the ETB selective agonist IRL 1620. The contractile effect of IRL 1620 is reduced in the presence of BQ-788 but is not influenced by BQ-123. The RbJV responds to ETA and to IRL 1620 with contractions that are reduced by both BQ-123 and BQ-788, respectively. The RbJV appears to be a mixed ETA and ETB system in which the two functional sites play an equivalent role in the stimulatory contractile response.
Thus, contractile ETA and ETB receptors have been found in arterial and venous vessels of the rabbit and some of these vessels provide sensitive and selective (either ETA or ETB) preparations that appear to be adequate for pharmacological studies on ET receptor agonists or antagonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bax WA, Bos E, Saxena PR: Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol 239: 267–268, 1993
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415, 1988
Haynes WG, Clarke JG, Cockcroft JR, Webb DJ: Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol 17: S284-S286, 1991
Itoh H, Higuchi H, Hiraoka N, Ito M, Konishi T, Nakano T, Lederis K: Contraction of rat thoracic aorta strips by endothelin-1 in the absence of extracellular Ca2+. Br J Pharmacol 104: 847–852, 1991
Douglas SA, Elliott JD, Ohlstein EH: Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. Eur J Pharmacol 221: 315–324, 1992
Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR: Comparative studies with the endothelin receptor antagonists BQ-123 and PD 14893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol 22: S117-S120, 1993
Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 107: 858–860, 1992
Karne S, Jayawickreme CK, Lerner MR: Cloning and characterization of an endothelin-3 specific receptor (ETc receptor) from xenopus laevis dermal melaphores. J Biol Chem 268: 19126–19133, 1993
Regoli D, D'Orleans-Juste P, Rouissi N, Rhaleb NE: Vasoactive peptides and characterization of their receptors. Regul Peptides 45: 323–340, 1993
Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, Ramuz H: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Therap 270: 228–235, 1994
Takai M, Umemura I, Yamasaki K, Watanabe T, Fujitani Y, Oda K, Urade Y, Inui T, Yamamura T, Okada T: A potent and specific agonists, Suc-[Glu9,Ala11, 15]-endothelin-1(8–21), IRL I620, for the ETB receptor. Biochem Biophys Res Commun 184: 953–959, 1992
Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M: Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50: 247–255, 1992
Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M: Biochemical and pharmacological profile of a potent and selective endothelin B receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91: 4892–4896, 1994
Arunlakshana O, Schild HO: Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48–58, 1959
Tallarida RJ, Murray RB: Manual of Pharmacological calculation with computer programs. Springer-Verlag, New York, 1986
Schild HO: pA, a new scale for the measurement of drug antagonism: Br J Pharmacol 2: 189–206, 1947
Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Loffler BM, Muller M, Neidhart W, Ramuz H: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365: 759–761, 1993
Regoli D. Boudon A, Fauchere JL: Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46: 551–599, 1994
Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, Nishikibe M: Synergistic inhibition by BQ-123 and BQ-788 of endothelin-linduced contractions of the rabbit pulmonary artery. Br J Pharmacol 113: 336–338, 1994
Moreland S, McMullen D, Abboa-Offei B, Seymour A: Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature. Br J Pharmacol 112: 704–708, 1994
Regoli D, Gobeil F, Nguyen QT, Jukic D, Seoane PR, Salvino JM, Sawutz DG: Bradykinin receptor types and B2 subtypes. Life Sci 55: 735–749, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caló, G., Gratton, J.P., Télémaque, S. et al. Pharmacology of endothelins: vascular preparations for studying ETA and ETB receptors. Mol Cell Biochem 154, 31–37 (1996). https://doi.org/10.1007/BF00248458
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00248458